Search Results 91-100 of 10642 for pv

  1. Clinical trials - Gastroenterology and Hepatology

    Borderline Resectable Pancreatic Cancer - Tumor-vessel interface ≥180° of vessel wall circumference, and/or reconstructible occlusion of the SMV-PV. - Tumor- ...

  2. Search Publications by Mayo Clinic Authors

    Wagh MS, Draganov PV. · Gastroenterology. 2021 Jan; 160 (1):10-14 Epub 2020 Nov 19 ...

  3. A Study to Evaluate the Effectiveness, Safety, and Tolerability of Efgartigimod PH20 SC in Patients with Pemphigus - Mayo Clinic

    ... (PV) or Pemphigus Foliaceus (PF). Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and previous treatments ...

  4. Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF - Mayo Clinic

    ... PV MF), or Post-essential Thrombocythemia Myelofibrosis (post-ET MF). Participation eligibility. Participant eligibility includes age, gender, type and stage ...

  5. Study of LY2784544 Testing Alternative Dosing in Participants with Myeloproliferative Neoplasms - Mayo Clinic

    Have a diagnosis of polycythemia vera (PV), essential thrombocythemia (ET), or myelofibrosis (MF, primary or secondary) PV and ET participants must have ...

  6. Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis - Mayo Clinic

    ... PV/ET MF) who have not yet received treatment with a Janus kinase inhibitor (JAK inhibitor). Participants will be randomized to receive either MMB or ...

  7. Clinical trials - Oncology (Medical)

    Borderline Resectable Pancreatic Cancer - Tumor-vessel interface ≥180° of vessel wall circumference, and/or reconstructible occlusion of the SMV-PV. - Tumor- ...

  8. Study of Canakinumab in Patients With Myelofibrosis - Mayo Clinic

    The purpose of this study is to estimate the effectiveness of Canakinumab treatment in patients with primary myelofibrosis (PMF), post PV-MF (Post ...

  9. CC-4047 in Treating Patients With Myelofibrosis - Mayo Clinic

    ... (PV) myelofibrosis requiring therapy. De novo presentation (i.e., agnogenic myeloid metaplasia AND post ET or post PV myelofibrosis); Developed after an ...

  10. Borderline Resectable Pancreatic Cancer - Tumor-vessel interface ≥180° of vessel wall circumference, and/or reconstructible occlusion of the SMV-PV. - Tumor- ...